JP2022503847A - 治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞 - Google Patents

治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞 Download PDF

Info

Publication number
JP2022503847A
JP2022503847A JP2021517408A JP2021517408A JP2022503847A JP 2022503847 A JP2022503847 A JP 2022503847A JP 2021517408 A JP2021517408 A JP 2021517408A JP 2021517408 A JP2021517408 A JP 2021517408A JP 2022503847 A JP2022503847 A JP 2022503847A
Authority
JP
Japan
Prior art keywords
cells
nk1r
cell
stem cells
progenitor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517408A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022503847A5 (https=
JPWO2020069215A5 (https=
Inventor
イアン マクニース，
ピーター アルトマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocardia Inc
Original Assignee
Biocardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocardia Inc filed Critical Biocardia Inc
Publication of JP2022503847A publication Critical patent/JP2022503847A/ja
Publication of JP2022503847A5 publication Critical patent/JP2022503847A5/ja
Publication of JPWO2020069215A5 publication Critical patent/JPWO2020069215A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2021517408A 2018-09-27 2019-09-26 治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞 Pending JP2022503847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737627P 2018-09-27 2018-09-27
US62/737,627 2018-09-27
PCT/US2019/053293 WO2020069215A1 (en) 2018-09-27 2019-09-26 Bone marrow derived neurokinin-1 receptor positive (nk1r+) precursor cells for therapeutic applications

Publications (3)

Publication Number Publication Date
JP2022503847A true JP2022503847A (ja) 2022-01-12
JP2022503847A5 JP2022503847A5 (https=) 2022-09-30
JPWO2020069215A5 JPWO2020069215A5 (https=) 2022-09-30

Family

ID=69945385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517408A Pending JP2022503847A (ja) 2018-09-27 2019-09-26 治療適用のための骨髄由来ニューロキニン－１受容体陽性（ｎｋ１ｒ＋）前駆細胞

Country Status (4)

Country Link
US (2) US11642377B2 (https=)
EP (1) EP3856203A4 (https=)
JP (1) JP2022503847A (https=)
WO (1) WO2020069215A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020069215A1 (en) 2018-09-27 2020-04-02 Biocardia, Inc. Bone marrow derived neurokinin-1 receptor positive (nk1r+) precursor cells for therapeutic applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
EP2608797B1 (en) * 2010-08-27 2015-09-23 University of Miami Bone marrow derived cd271 precursor cells for cardiac repair
WO2020069215A1 (en) 2018-09-27 2020-04-02 Biocardia, Inc. Bone marrow derived neurokinin-1 receptor positive (nk1r+) precursor cells for therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICROCIRCULATION, vol. Vol. 24, e12394, JPN6023025730, 2017, pages 1 - 9, ISSN: 0005089955 *
THE JOURNAL OF IMMUNOLOGY, vol. 179, JPN6023025729, 2007, pages 3342 - 3350, ISSN: 0005089956 *

Also Published As

Publication number Publication date
EP3856203A4 (en) 2022-02-23
US20240082310A1 (en) 2024-03-14
US20200101113A1 (en) 2020-04-02
US11642377B2 (en) 2023-05-09
WO2020069215A1 (en) 2020-04-02
EP3856203A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
US20230071551A1 (en) Bone Marrow Derived CD271 Precursor Cells for Cardiac Repair
US8343479B2 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
CA2488346C (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
US10709742B2 (en) Method to amplify cardiac stem cells in vitro and in vivo
US20240082310A1 (en) Bone marrow derived neurokinin-1 receptor positive (nk1r+) mesenchymal stem cells for therapeutic applications
Akar et al. Regenerative Medicine for Cardiovascular Disorders‐New Milestones: Adult Stem Cells
EP2205251A1 (en) A method to amplify cardiac stem cells in vitro and in vivo
Fazel Cardiac repair and not regeneration after myocardial infarction: the role and therapeutic utility of the c-kit
Taldone et al. Allogeneic versus Autologous Source: Comparative Effects
Fazel Cardiac repair and not regeneration after myocardial infarction: the role and therapeutic utility of the c-kitSCF pathway.
Gleeson Mesenchymal stem cell therapy for the treatment of myocardial

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240607

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240701

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240927